An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia

• Main Authors: Charlton, Michael R., Alam, Altaf, Shukla, Akash, Dashtseren, Bekhbold, Lesmana, Cosmas Rinaldi Adithya, Duger, Davadoorj, Payawal, Diana Alcantara, Duy Cuong, Do, Jargalsaikhan, Ganbolor, Cua, Ian Homer Yee, Sollano, Jose Decena, Singh, Karam Romeo, Madan, Kaushal, Win, Khin Maung, Kyi, Khin Pyone, Tun, Kyaw Soe, Salih, Mohd., Rastogi, Mukul, Saraf, Neeraj, Thuy, Pham Thi Thu, Hien, Pham Tran Dieu, Gani, Rino Alvani, Mohamed, Rosmawati, Tanwandee, Tawesak, Piratvisuth, Teerha, Sukeepaisarnjaroen, Wattana, Naing, Win, Hashmi, Zahid Yasin
• Format: Article
• Published: Springer 2020
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: http://eprints.um.edu.my/36549/

Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key i...